Grant: Collaborative Health Research Projects
University of Calgary
$194,280.00
Rapid in vitro screening of nanomaterial distributions and toxicity
EF 2013-14
Résumé
Develop screening tools for rapid toxicity and biodistribution assessment of nanomaterials. Using our biological models and findings (from first CHRP grant), we will develop devices and protocols to rapidly screen for the toxicity of nanomaterials. Ourcurrent CHRP grant has shown the following: 1) uptake of nanoparticles (NPs) from the blood stream depends primarily on charge and then on size; 2) endocytosis of NPs into vascular endothelial cells also depends critically on the charge and size of the NP and on the conditions of blood flow; 3) the aggregation state of the NPs in the blood stream affects uptake.NOVELTY: The screening of nanoparticle toxicity is laborious and expensive. Given the large number of different NP compositions, surface chemistries, shapes, and aggregation states, it is not realistic to evaluate each of these conditions using standard toxicological strategies. Here we propose to develop devices and protocols that would accelerate the analysis of NP toxicity and enable researchers to establish the properties of a nanomaterial responsible for certain toxic responses. The approach to rapid screening will be a two-stage assessment. The first stage will screen the nanomaterials' propensity to form aggregates, to associate with serum proteins, and to partition into a model cell membrane environment. The second stage will assess the distribution of NPs in a blood vessel mimetic flow chamber.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
413584-2012
Name nom
Cramb, David
Department département
Chemistry
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
194280
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
2 & 3
Nb partie
3
Application title
Rapid in vitro screening of nanomaterial distributions and toxicity
Keyword
NSERC
Application summary
Develop screening tools for rapid toxicity and biodistribution assessment of nanomaterials. Using our biological models and findings (from first CHRP grant), we will develop devices and protocols to rapidly screen for the toxicity of nanomaterials. Ourcurrent CHRP grant has shown the following: 1) uptake of nanoparticles (NPs) from the blood stream depends primarily on charge and then on size; 2) endocytosis of NPs into vascular endothelial cells also depends critically on the charge and size of the NP and on the conditions of blood flow; 3) the aggregation state of the NPs in the blood stream affects uptake.NOVELTY: The screening of nanoparticle toxicity is laborious and expensive. Given the large number of different NP compositions, surface chemistries, shapes, and aggregation states, it is not realistic to evaluate each of these conditions using standard toxicological strategies. Here we propose to develop devices and protocols that would accelerate the analysis of NP toxicity and enable researchers to establish the properties of a nanomaterial responsible for certain toxic responses. The approach to rapid screening will be a two-stage assessment. The first stage will screen the nanomaterials' propensity to form aggregates, to associate with serum proteins, and to partition into a model cell membrane environment. The second stage will assess the distribution of NPs in a blood vessel mimetic flow chamber.